Marcel M. Verbeek
#163,178
Most Influential Person Now
Marcel M. Verbeek's AcademicInfluence.com Rankings
Marcel M. Verbeekphilosophy Degrees
Philosophy
#9484
World Rank
#13052
Historical Rank
Logic
#6458
World Rank
#7977
Historical Rank
Download Badge
Philosophy
Why Is Marcel M. Verbeek Influential?
(Suggest an Edit or Addition)Marcel M. Verbeek's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) (1139)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study (2009) (566)
- Prediction of poor outcome within the first 3 days of postanoxic coma (2006) (528)
- Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury (2004) (392)
- The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. (2019) (379)
- Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. (2010) (349)
- A Practical Guide to Immunoassay Method Validation (2015) (320)
- Prognosis of coma after therapeutic hypothermia: A prospective cohort study (2012) (320)
- Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. (2014) (293)
- Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. (2012) (291)
- Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains (2006) (226)
- Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis (2013) (216)
- MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid (2014) (209)
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
- Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders (2003) (189)
- Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. (1994) (189)
- Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. (2010) (186)
- A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease (2009) (179)
- Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. (2005) (176)
- Pathogenesis of cerebral amyloid angiopathy (2003) (168)
- Impact of molecular imaging on the diagnostic process in a memory clinic (2013) (166)
- Age and diagnostic performance of Alzheimer disease CSF biomarkers (2012) (163)
- Rapid Degeneration of Cultured Human Brain Pericytes by Amyloid β Protein (1997) (157)
- Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency (2010) (156)
- Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy (2009) (151)
- The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice (2017) (147)
- Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. (2007) (136)
- No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial (2008) (136)
- Small heat shock proteins inhibit amyloid-β protein aggregation and cerebrovascular amyloid-β protein toxicity (2006) (134)
- Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency (2017) (133)
- Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients (2003) (133)
- Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer’s Disease (2007) (124)
- The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. (2010) (123)
- Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. (1999) (123)
- CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease (2007) (121)
- Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis (2018) (119)
- Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases (2015) (118)
- MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid (2015) (117)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- CSF neurofilament proteins in the differential diagnosis of dementia (2007) (115)
- T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. (1995) (113)
- Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. (1994) (112)
- Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: Focus on the role of hypocretin and melatonin (2013) (111)
- Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. (2006) (110)
- Cerebrospinal Fluid Glucose and Lactate: Age-Specific Reference Values and Implications for Clinical Practice (2012) (103)
- CSF α-synuclein does not differentiate between parkinsonian disorders (2012) (103)
- Inhibition of α‐synuclein aggregation by small heat shock proteins (2011) (102)
- Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. (2013) (97)
- Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. (2006) (97)
- Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases (2003) (94)
- Recommended Citation (1998) (93)
- Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. (2013) (93)
- MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy (2016) (92)
- LRP1 shedding in human brain: roles of ADAM10 and ADAM17 (2009) (92)
- Small heat shock protein HspB8: its distribution in Alzheimer’s disease brains and its inhibition of amyloid-β protein aggregation and cerebrovascular amyloid-β toxicity (2006) (92)
- Expression pattern of apoptosis-related markers in Huntington’s disease (2005) (90)
- Neurofilament ELISA validation. (2010) (90)
- Current state and future directions of neurochemical biomarkers for Alzheimer's disease. (2007) (88)
- Combination of serum markers related to several mechanisms in Alzheimer’s disease (2003) (88)
- Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment (2012) (87)
- Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. (2009) (86)
- Rapid degeneration of cultured human brain pericytes by amyloid beta protein. (1997) (86)
- Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. (2012) (85)
- Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease (2011) (83)
- CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. (2010) (81)
- Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice (2014) (80)
- α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism (2019) (80)
- Collagen XVIII: a Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer's Disease Brains (2002) (79)
- Serum NFL discriminates Parkinson disease from atypical parkinsonisms (2019) (79)
- Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome (2012) (78)
- Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease (2004) (76)
- The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. (2016) (75)
- An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. (2005) (74)
- Biomarkers in spinal cord injury (2009) (74)
- Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. (2007) (74)
- The role of amyloid in the pathogenesis of Alzheimer's disease. (1997) (73)
- CSF neurofilament protein analysis in the differential diagnosis of ALS (2009) (73)
- Endotoxemia-induced inflammation and the effect on the human brain (2010) (72)
- Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels (2010) (72)
- Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
- MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer* (2005) (72)
- The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review (2018) (72)
- Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. (2008) (72)
- Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion (2003) (71)
- CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. (2014) (71)
- TDP-43 plasma levels are higher in amyotrophic lateral sclerosis (2012) (71)
- Ten steps to identify atypical parkinsonism (2006) (70)
- Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques (2002) (68)
- Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration (2010) (67)
- Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. (1997) (65)
- Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects (2014) (65)
- GLUT1 deficiency syndrome into adulthood: a follow-up study (2014) (64)
- Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. (2006) (64)
- Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. (2018) (64)
- Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative (2015) (62)
- Genome-Wide Identification of Streptococcus pneumoniae Genes Essential for Bacterial Replication during Experimental Meningitis (2010) (62)
- Methods for analysis of amyloid-β aggregates. (2012) (60)
- Measurement of glial fibrillary acidic protein in blood: an analytical method. (2002) (60)
- Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies (2020) (60)
- Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease (2010) (60)
- Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders (2016) (58)
- Insulin inhibits amyloid β-induced cell death in cultured human brain pericytes (2004) (57)
- Increased GFAP and S100β but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity (2006) (57)
- The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease (2019) (57)
- Serum- and CSF-concentrations of brain specific proteins in hydrocephalus (2003) (56)
- Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy (2011) (55)
- Amyloid‐β‐induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype (2000) (53)
- Distribution of Aβ-associated proteins in cerebrovascular amyloid of Alzheimer’s disease (1998) (52)
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
- CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia (2006) (52)
- Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains (2001) (52)
- Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. (2012) (51)
- Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. (2007) (48)
- Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers (2012) (48)
- Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A‚-containing lesions in brains of patients with dementia of the Alzheimer type (1996) (47)
- Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease (2020) (47)
- Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood‐brain barrier (2016) (46)
- Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease (2002) (45)
- Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects (2012) (45)
- Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. (2012) (45)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Apolipoprotein E protects cultured pericytes and astrocytes from D-Aβ1–40-mediated cell death (2010) (44)
- Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid (2008) (44)
- Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet (2013) (43)
- Small Heat Shock Proteins Induce a Cerebral Inflammatory Reaction (2011) (41)
- Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism (2015) (41)
- Apolipoprotein E Genotype Regulates Amyloid-β Cytotoxicity (2005) (40)
- Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS (2017) (40)
- Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2017) (40)
- CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders (2015) (39)
- Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease. (2015) (39)
- CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. (2010) (39)
- Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis (2021) (38)
- Ancillary investigations to diagnose parkinsonism: a prospective clinical study (2015) (38)
- Serum Neuron-Specific Enolase Levels from the Same Patients Differ Between Laboratories: Assessment of a Prospective Post-cardiac Arrest Cohort (2013) (38)
- Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion (2009) (38)
- Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms (2019) (38)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (38)
- Animal models of cerebral amyloid angiopathy. (2017) (37)
- CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. (2007) (37)
- CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement (2006) (37)
- Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism (2015) (36)
- Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene (2007) (36)
- Technical and biochemical factors affecting cerebrospinal fluid 5-MTHF, biopterin and neopterin concentrations. (2008) (36)
- Accumulation of the Amyloid-β Precursor Protein in Multivesicular Body-like Organelles (2002) (36)
- Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. (2016) (35)
- A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi–Goutières syndrome (2010) (35)
- Tyrosine hydroxylase deficiency with severe clinical course. (2009) (35)
- A more efficient enzyme-linked immunosorbent assay for measurement of α-synuclein in cerebrospinal fluid (2008) (35)
- Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. (2016) (35)
- The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases (2015) (34)
- Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson’s Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study (2016) (33)
- The mitochondrial toxin 3‐nitropropionic acid induces differential expression patterns of apoptosis‐related markers in rat striatum (2001) (33)
- Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. (2010) (33)
- Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study (2015) (32)
- CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls (2016) (32)
- Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. (2017) (32)
- Cerebral Amyloid Angiopathy in Alzheimer’s Disease and Related Disorders (2000) (32)
- CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. (2011) (32)
- Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology (2019) (32)
- Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases (2010) (31)
- CSF hypocretin-1 levels are normal in multiple-system atrophy. (2008) (31)
- Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study (2018) (31)
- Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias (2014) (30)
- Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene‐related dementias: a morphological study (2006) (30)
- Meningoencephalitis caused by Streptococcus pneumoniae: a diagnostic and therapeutic challenge (2005) (30)
- Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Aβ40 (DAβ1-40) are modulated by sulfate moieties of heparin (2010) (30)
- Dickkopf‐related protein 3 is a potential Aβ‐associated protein in Alzheimer's Disease (2015) (30)
- C-Reactive Protein, Plasma Amyloid-&bgr; Levels, and Their Interaction With Magnetic Resonance Imaging Markers (2018) (29)
- CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders (2015) (29)
- Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. (2004) (28)
- Serum GFAP levels in optic neuropathies (2012) (27)
- Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. (2008) (27)
- Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome (2011) (27)
- Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis (2014) (27)
- &bgr;-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy (2017) (25)
- CSF levels of growth factors and plasminogen activators in leptomeningeal metastases (2006) (25)
- Inhibition of amyloid-β-induced cell death in human brain pericytes in vitro (2002) (24)
- Human brain pericytes as a model system to study the pathogenesis of cerebrovascular amyloidosis in Alzheimer's disease. (1999) (24)
- An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter (2015) (24)
- Has CXCL13 an added value in diagnosis of neurosyphilis? (2015) (24)
- A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers (2013) (24)
- Distribution of A beta-associated proteins in cerebrovascular amyloid of Alzheimer's disease. (1998) (23)
- Two Greek siblings with sepiapterin reductase deficiency. (2008) (23)
- Diagnosis of progressive supranuclear palsy: can measurement of tau forms help? (2012) (22)
- Increased plasma amyloid-β42 protein in sporadic inclusion body myositis (2009) (22)
- Cras Meningoencephalitis caused by Streptococcus pneumoniae : a diagnostic and therapeutic challenge Diagnosis with diffusion-weighted MRI leading to treatment with corticosteroids (2005) (22)
- Comparison of methods for the detection of oligoclonal IgG bands in cerebrospinal fluid and serum: results of the Dutch Quality Control survey. (2002) (20)
- Cerebrospinal fluid Aβ42 levels in multiple system atrophy (2004) (19)
- Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid (2021) (19)
- 3-Nitropropionic acid induces cell death and mitochondrial dysfunction in rat corticostriatal slice cultures (2002) (19)
- Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases (2016) (19)
- Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
- Multiple diagnostic tests are needed to assess multiple causes of dementia. (2006) (18)
- Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis (2010) (18)
- Transient Induction of E‐Selectin Expression Following TNFα‐Based Isolated Limb Perfusion in Melanoma and Sarcoma Patients Is Not Tumor Specific (1996) (17)
- Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged (2015) (17)
- Diagnostic accuracy of the clapping test in Parkinsonian disorders (2007) (16)
- Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders (2009) (16)
- Differential gene expression in human brain pericytes induced by amyloid‐β protein (2004) (16)
- White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. (2016) (16)
- A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques (2004) (16)
- Child Neurology: Differential diagnosis of a low CSF glucose in children and young adults (2013) (16)
- Amyloid β induces cellular relocalization and production of agrin and glypican-1 (2009) (16)
- Hourly analysis of cerebrospinal fluid glucose shows large diurnal fluctuations (2016) (15)
- Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome (2017) (15)
- Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage (2020) (15)
- Identification of coronin‐1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis (2013) (15)
- Cerebrospinal fluid tau levels in frontotemporal dementia (2005) (15)
- Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization (2019) (15)
- Plasma A&bgr; (Amyloid-&bgr;) Levels and Severity and Progression of Small Vessel Disease (2018) (14)
- Mapping the multicausality of Alzheimer’s disease through group model building (2020) (14)
- Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome (2018) (14)
- Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease) (2009) (14)
- Limited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease (2010) (13)
- The paradox of hyperdopaminuria in aromatic L-amino Acid deficiency explained. (2012) (13)
- Downregulation of synapse-associated protein expression and loss of homeostatic microglial control in cerebrospinal fluid of infectious patients with delirium and patients with Alzheimer’s disease (2020) (13)
- CSF protein profiling using Multiplex Immuno-assay (2006) (13)
- Cerebral level of vGlut1 is increased and level of glycine is decreased in TgSwDI mice. (2014) (13)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (12)
- Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome (2012) (12)
- The diagnostic value of CSF amyloid-β(43) in differentiation of dementia syndromes. (2013) (12)
- Autoimmune Encephalitis Resembling Dementia Syndromes (2021) (12)
- Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines (2021) (12)
- Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease? (2010) (12)
- Mechanisms of peripheral levodopa resistance in Parkinson’s disease (2022) (12)
- CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans (2011) (12)
- Inhibition of amyloid-beta-induced cell death in human brain pericytes in vitro. (2002) (12)
- Creatine protects against 3-nitropropionic acid-induced cell death in murine corticostriatal slice cultures (2004) (12)
- CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD (2020) (12)
- Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. (2018) (11)
- CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases. (2006) (11)
- Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation (2014) (11)
- Hypoglycorrhachia: A simple clue, simply missed (2001) (11)
- Brain specific proteins in serum: do they reliably reflect brain damage? (2002) (11)
- Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood (2021) (11)
- TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies (2010) (11)
- Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. (2004) (11)
- Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson’s disease and controls (2013) (11)
- Amyloid beta-42 (Aβ-42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments (2015) (10)
- Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. (2017) (10)
- Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy (2019) (10)
- Replicated Evidence of Absence of Association between Serum S100B and (Risk of) Psychotic Disorder (2013) (10)
- Parkinson’s Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism (2018) (10)
- Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion (2022) (10)
- CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis (2009) (10)
- Multicenter Analytical Validation of Aβ40 Immunoassays (2017) (10)
- Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children (2021) (10)
- Serum angiogenin levels are elevated in ALS, but not Parkinson's disease (2014) (9)
- β-Amyloid in CSF (2017) (9)
- Cerebral Amyloid Angiopathy with Severe Secondary Vascular Pathology: A Histopathological Study (2005) (9)
- Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study (2020) (9)
- Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases (2006) (9)
- CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC) (2009) (9)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (9)
- A rational design to create hybrid β-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-β (2011) (9)
- Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach (2021) (8)
- Off-label use of aducanumab for cerebral amyloid angiopathy (2021) (8)
- Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions (2017) (8)
- Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls (2018) (8)
- Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2 (2012) (8)
- Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public (2019) (7)
- Confirmation of neurometabolic diagnoses using age‐dependent cerebrospinal fluid metabolomic profiles (2020) (7)
- CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation. (2009) (7)
- Degeneration of Human Cerebrovascular Smooth Muscle Cells and Pericytes Caused by Amyloid β Protein (2000) (7)
- Detection of tau forms in CSF requires sensitive techniques (2012) (7)
- The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects. (2005) (7)
- Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase (2021) (7)
- Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming (2021) (7)
- Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. (2012) (7)
- Chronic herpes simplex virus encephalitis in childhood. (2006) (6)
- Saffold cardiovirus and multiple sclerosis: no evidence for an association (2014) (6)
- Clinical presentation and long‐term follow‐up of dopamine beta hydroxylase deficiency (2020) (6)
- Induction of a-Smooth Muscle Actin Expression in Cultured Human Brain Pericytes by Transforming Growth Factor-f31 (2007) (6)
- Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease (2020) (6)
- Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. (2017) (6)
- Alzheimer biomarkers and clinical Alzheimer disease were not associated with increased cerebrovascular disease in a memory clinic population. (2014) (6)
- Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity (2020) (6)
- LRP 1 shedding in human brain : roles of ADAM 10 and ADAM 17 (2017) (6)
- Cerebrospinal Fluid Tau and Amyloid β Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients (2010) (5)
- Cerebral folate deficiency syndrome. (2005) (5)
- Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease. (2008) (5)
- Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. (2020) (5)
- [The possible suppression of Alzheimer's disease by nonsteroidal anti-inflammatory drugs]. (2002) (5)
- Correction to: Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies (2020) (5)
- MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy (2021) (5)
- Glial fibrillary acidic protein in Guillain‐Barré syndrome: Methodological issues (2009) (5)
- Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes (2021) (4)
- White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers (2020) (4)
- Diagnostic challenges in parkinsonism (2011) (4)
- Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42 (2020) (4)
- Monoamine oxidase A activity in fibroblasts as a functional confirmation of MAOA variants (2020) (4)
- Sleep-Cognition Hypothesis In maritime Pilots, what is the effect of long-term work-related poor sleep on cognition and amyloid accumulation in healthy middle-aged maritime pilots: methodology of a case–control study (2019) (4)
- Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease (2020) (4)
- Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study. (2015) (4)
- Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy (2021) (4)
- Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports (2010) (3)
- Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. (2021) (3)
- Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2018) (3)
- Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder? (2017) (3)
- CSF α-synuclein correlates with CSF neurogranin in late-life depression (2020) (3)
- MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid (2015) (3)
- LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
- Analytical performance of a kinetic method for the determination of lactate dehydrogenase catalytic concentration in cerebrospinal fluid. (2004) (3)
- CSF alpha synuclein and late-life depression CSF alpha synuclein correlates with CSF neurogranin in late-life depression (2020) (3)
- CSF alpha-synuclein is not diagnostic for dementia with Lewy bodies, but related to cognitive decline (2010) (2)
- Concordance of CSF RT-QuIC across the European Creutzfeldt-Jakob Disease surveillance network. (2022) (2)
- Expression of glutamate-related proteins vGlut1 and PSD-95 changed in a transgenic mouse model of Alzheimer's disease (2011) (2)
- Expression of five miRNA targets in hippocampus and cerebrospinal fluid in Alzheimer's disease (2012) (2)
- A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example (2015) (2)
- [Inflammatory mechanisms in the pathogenesis of Alzheimer's disease]. (1997) (2)
- Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease (2021) (2)
- Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) (2)
- [Diagnosis in cerebrospinal fluid: possible applications in neurological practice]. (2005) (2)
- P3-045 Tau protein phosphorylated at threonine 181 in cerebrospinal fluid as a possible biomarker for Alzheimer's disease (2004) (2)
- The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role (2022) (2)
- Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? (2015) (1)
- Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen‐encapsulated human umbilical cord mesenchymal stem cells (2020) (1)
- Cerebrospinal fluid biomarkers for Alzheimer's disease and specific cognitive decline in subjects with mild cognitive impairment (2012) (1)
- CSFBiomarkersandIncipientAlzheimerDisease in Patients With Mild Cognitive Impairment (2009) (1)
- P4-312: Treatment of APPswe/PS1dE9 mice with Enoxaparin improves cognitive impairment (2008) (1)
- C-REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY (2018) (1)
- Factors associated with mortality in early stages of parkinsonism (2022) (1)
- Elevated CSF levels of neurofilament proteins in sporadic Creutzfeldt-Jakob disease (2009) (1)
- MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy (2016) (1)
- Liquoronderzoek in de differentiële diagnostiek van multipele systeematrofie. (2007) (1)
- Oxidized Pin1 and alpha-synuclein in the cerebrospinal fluid as putative biomarkers for Alzheimer's and Parkinson's diseases (2012) (1)
- Differential expression of heparan sulfate proteoglycans in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. (2001) (1)
- POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA (2007) (1)
- International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease (2020) (1)
- Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson’s Disease (2022) (1)
- CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER'S DISEASE: ARE THE HYPOTHESES MORE DYNAMIC THAN THE BIOMARKERS? (2010) (1)
- Prevalence of sporadic cerebral amyloid angiopathy: A systematic review and meta‐analysis (2021) (1)
- P4-039 Small heat shock protein B8 associates with Aβ and inhibits both its aggregation and cerebrovascular toxicity (2006) (1)
- SPAG16 isoform 2 as a novel autoantigen in multiple sclerosis (2010) (1)
- Aβ-Associated Proteins in Cerebral Amyloid Angiopathy (2000) (1)
- ASSOCIATION BETWEEN NOCTURNAL AMYLOID BETA FLUCTUATIONS AND SLEEP (2017) (1)
- Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment (2021) (1)
- Concordance of cerebrospinal fluid real‐time quaking‐induced conversion across the European Creutzfeldt–Jakob Disease Surveillance Network (2022) (1)
- Cerebrospinal fluid amyloid beta40 and the amyloid beta42/40 ratio in differentiating Alzheimer's disease from other dementias (2009) (0)
- Author response for "Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming" (2020) (0)
- Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase (2021) (0)
- CSF Neurotransmitter Metabolites and Brain-Specific Proteins Differentiate Dementia with Lewy Bodies from Alzheimer’s (2011) (0)
- Hypoglycorrachie ten gevolge van type 1-glucosetransportdeficientie. (2001) (0)
- The accuracy of the arginine growth hormone test in Parkinsonism (2008) (0)
- A beta 43 in human Alzheimer's disease: effects of active A beta 42 immunization (2019) (0)
- Small heat shock proteins associated with extracellular Aβ induce an inflammatory reaction in cultured human cerebrovascular cells (2011) (0)
- Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease (2023) (0)
- BINDING OF THE AB43 PEPTIDE TO APOLIPOPROTEIN E AND ITS ROLE IN CLEARANCE (2014) (0)
- MICRO-RNAS AS NOVEL BIOMARKERS IN AD: DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID (2014) (0)
- MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy (2021) (0)
- Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42 (2020) (0)
- The distribution of different heparan sulfate proteoglycans in cerebrovascular amyloid angiopathy of Alzheimer's disease brains (2000) (0)
- Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls (2021) (0)
- Low glycine levels in brain homogenates of TgSwDI mice compared to wild-type mice (2011) (0)
- P1-178 Small heat shock proteins affect amyloid-β protein aggregation and inhibit cerebrovascular amyloid-β protein toxicity (2004) (0)
- P4-035 Amyloid β protein receptors in Alzheimer’s disease (2006) (0)
- O4-04-01 Induction of heparan sulfate proteoglycans production by Aβ (2004) (0)
- Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) (0)
- ABCA-1-mediated beta-amyloid uptake by cells of the blood-brain barrier (2012) (0)
- Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes (2023) (0)
- Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example (2015) (0)
- Amyloid-associated proteins (AAPs) in familial British dementia (FBD) and familial Danish dementia (FDD) (2005) (0)
- TDP-43 and tau as cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes (2012) (0)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (0)
- Complexes of amyloid β and Amyloid-β-crystallin as potential biomarkers for early stage Alzheimer's disease (2011) (0)
- Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy (2021) (0)
- Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy (2020) (0)
- Proteomic analysis of brain tissue from the TgSwDI mouse model (2012) (0)
- CSF markers as predictors for Alzheimer's disease in subjects with MCI: Effect of APOE genotype-adjusted cut offs (2010) (0)
- Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage (2020) (0)
- The adhesion of T lymphocytes to human endothelial cells and brain pericytes is differentially regulated (1994) (0)
- Co-localization of heparan sulfate proteoglycans with the amyloid beta protein in APPswe/PS1dE9 mice is limited (2011) (0)
- CORRELATIONS OF CSF BIOMARKER LEVELS WITH LATERAL VENTRICULAR CSF VOLUMES (2014) (0)
- Catalase inhibits amyloid β-induced cell death in human brain pericytes in vitro (2000) (0)
- UvA-DARE ( Digital Academic Repository ) Postanoxic coma : prognosis after therapeutic hypothermia (2012) (0)
- ICAM expression and microglial activation in Alzheimer senile plaques: Indicators of an inflammatory response (1994) (0)
- A single night of sleep deprivation increases cerebrospinal fluid beta-amyloid 42 protein in healthy male volunteers (2013) (0)
- First Multicenter Qualification of an Assay (INNO-BIA Plasma Aß Forms Assay) for Measurement of ß-amyloid Proteins as Part of US-ADNI Efforts for Biomarker Qualification (2010) (0)
- Ten steps to identify atypical parkinsonism. Commentary (2006) (0)
- P205 – 1655 Autosomal dominant guanine triphosphate cyclohydrolase deficiency (GTPCH; Segawa's disease) (2013) (0)
- Reply to: Letter for: Decreased cerebrospinal fluid A β 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy (2023) (0)
- Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public (2019) (0)
- O3-03-01: Apolipoprotein E protects cerebrovascular cells and astrocytes from Aβ-mediated cell death (2008) (0)
- P2.061 The value of MRI in the early disease stages of parkinsonian disorders: a prospective three year follow-up study (2009) (0)
- Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach (2021) (0)
- Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease (2020) (0)
- Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy (2020) (0)
- Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions (2016) (0)
- Identification of novel potential antibody biomarkers in early multiple sclerosis (2010) (0)
- A prediction rule of CSF biomarkers for Alzheimer's disease in clinical practice (2011) (0)
- Taking a closer look at Spag16 in multiple sclerosis (2014) (0)
- Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization (2019) (0)
- Novel potential autoantibody biomarkers for clinically isolated syndrome (2011) (0)
- Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls (2018) (0)
- Cerebral vascular encephalopathy causes decreased cerebrospinal Aβ concentrations (2009) (0)
- P2-147 Seldi-tof MS analysis of amyloid beta peptides in CSF of patients with Alzheimer’s disease, vascular dementia and (neurological) controls: A pilot study (2006) (0)
- [Prion diseases in The Netherlands: twenty-nine years of surveillance]. (2022) (0)
- Researchced inflammation and the effect on the human brain (2010) (0)
- P1-379 Heparan sulphate proteoglycans affect the biological activity of Aβ (2006) (0)
- JAMA Paper supplement (2015) (0)
- Blood-CSF barrier dysfunction may affect CSF levels of angiogenesis in PD (2018) (0)
- Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)) (2015) (0)
- Decreased purine metabolite levels in cerebrospinal fluid of transgenic cerebral amyloid angiopathy rats (2021) (0)
- Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy (2023) (0)
- P1-445: Glycosaminoglycan sulfate moieties and chain length important for heparan sulfate proteoglycan interactions with amyloid-beta (2008) (0)
- Small heat shock proteins associated with extracellular Aβ induce an inflammatory reaction in human cerebal cells (2011) (0)
- P2-145 Cerebrospinal fluid neurofilament concentrations in dementia syndromes (2006) (0)
- PIPS one No Effect of One-Year Treatment with Indomethacin on Alzheimer ' s Disease Progression : A Randomized Controlled Trial (2017) (0)
- THE HCMEC/D3 CELL LINE IS NOT SUITABLE AS A MODEL FOR Aβ TRANSPORT BY THE HUMAN BLOOD-BRAIN BARRIER (2014) (0)
- ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE (2017) (0)
- Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficit (2022) (0)
- Preparation and detection of complexes of beta-amyloid with beta-amyloid–associated proteins (2012) (0)
- Improved CSF-based discrimination between Alzheimer’s disease patients and controls after correction for ventricular volumes (2015) (0)
- Development of a gold nanoparticle ELISA to detect low-abundant proteins in cerebrospinal fluid for diagnosis of Alzheimer's disease (2012) (0)
- Mechanism of apoptosis in Alzheimer's disease (1998) (0)
- Enoxaparin improves cognition of APPswe/PS1dE9 and TgSwDI mice with minor effect on amyloid β levels (2009) (0)
- Response in Multiple Sclerosis Target of the Humoral Autoimmune Sperm-Associated Antigen 16 Is a Novel (2014) (0)
- The impact of pre-analytical variables on measuring CSF biomarkers for Alzheimer’s disease diagnosis: A review (2019) (0)
- Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) (0)
- Inflammatory mechanisms and pericyte involvement in Alzheimer's disease (1996) (0)
- Amyloid Formation in Senile Plaques and Congophil-ic Angiopathy (1998) (0)
- Differential diagnosis of atypical parkinsonian syndromes in early phase of the disease: MRI approach (2010) (0)
- Beta-amyloid oligomer detection in cerebrospinal fluid and brain tissue (2012) (0)
- Serum S 100 B : A proxy marker for grey and (2018) (0)
- THE ASSOCIATION BETWEEN BLOOD-BRAIN-BARRIER DYSFUNCTION AND CSF P-TAU IS MEDIATED BY BETA-AMYLOID IN THE PRESENCE OF ELEVATED IL-6 (2018) (0)
- Factors associated with mortality in early stages of parkinsonism (2022) (0)
- Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2018) (0)
- Bio-barcode assay: Development of a sensitive technique to detect Alzheimer's disease at an early stage (2011) (0)
- Decreased cerebrospinal fluid Aβ 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. (2023) (0)
- The effect of chronic sleep deprivation on cognition in healthy middle aged men (2018) (0)
- Decreased miR-219 expression in MS: Clinical implications? (2014) (0)
- Hourly variability of cerebrospinal fluid biomarkers in Alzheimer patients and healthy elderly controls (2010) (0)
- Mechanisms of peripheral levodopa resistance in Parkinson’s disease (2022) (0)
- metastases Interleukin-8 CSF levels predict survival in patients with leptomeningeal (2006) (0)
- Time trends in demographic characteristics of participants and outcome measures in Parkinson’s disease research: A 19-year single-center experience (2023) (0)
- Analysis of Aβ transport in a human blood-brain barrier model (2012) (0)
- MDO04 Paroxysmal dopa-responsive dystonia and sepiapterine reductase deficiecy (2007) (0)
- Alzheimer's disease and cerebrovascular disease: Related or coexisting? (2011) (0)
- Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? (2015) (0)
- Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2 (2012) (0)
- Chitotriosidase activity in controls and multiple sclerosis (2010) (0)
- OXIDIZED PROTEINS IN THE CEREBROSPINAL FLUID AS PUTATIVE BIOMARKERS FOR ALZHEIMER ́S DISEASE (2011) (0)
- Anxiety is related to Alzheimer's disease markers in cerebrospinal fluid of subjects with mild cognitive impairment (2011) (0)
- Authors’ Response POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA (2007) (0)
- P4-226: LRP1 shedding in human brain: Roles of ADAM 10 and 17 (2008) (0)
- PLASMA AMYLOID β LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY (2018) (0)
- A-oligomers Quantification in Csf, and Their Clinical Value 4.2 Amyloid-oligomers Relate to Cognitive Decline in Alzheimer's Disease (2014) (0)
- The use of indexes in the interpretation of cerebrospinal fluid analyses (2010) (0)
- Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) (0)
- A disbalance of matrix metalloproteinases and their inhibitors in the cerebrospinal fluid from patients with cerebral amyloid angiopathy (2021) (0)
- Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study (2018) (0)
- Views on the Desirability of Diagnosing Sporadic Cerebral Amyloid Angiopathy with Biological Evidence (2022) (0)
- An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter (2015) (0)
- Novel Dutch FFI family with heterogeneous course and newly described histology (2012) (0)
- Amyloid β oligomers as a potential biomarker for early—stage Alzheimer's disease (2011) (0)
- 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
- Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy (2021) (0)
- Platelet‐derived growth factor receptor‐beta as a potential CSF biomarker for Alzheimer’s disease (2020) (0)
- Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS (2017) (0)
- P3-167 Specific association of small heat shock proteins with the pathological features of Alzheimer's and Parkinson's disease brains (2004) (0)
- P4-151: Sulphate moieties of heparan sulphate proteoglycans associated with senile plaques in Alzheimer's disease (2008) (0)
- MHPG as an additional marker for the differentiation of dementia with Lewy bodies from Alzheimer's disease, vascular dementia and frontotemporal dementia (2012) (0)
- CSF and MRI biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer's disease (2010) (0)
- Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Marcel M. Verbeek?
Marcel M. Verbeek is affiliated with the following schools:
